Physician profile
Robert M Hays
NPI 1043530165
$527.76
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $14.34.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $88.06 | 2019 | |
| Amgen INC. | $86.12 | 2019 | |
| Janssen Pharmaceuticals, INC | $63.43 | 2019-2020 | |
| Pfizer INC. | $40.64 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.04 | 2019 | |
| Sanofi Pasteur INC. | $27.07 | 2019 | |
| Glaxosmithkline, LLC. | $26.48 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.33 | 2019 | |
| Lilly USA, LLC | $23.26 | 2019 | |
| Genentech USA, INC. | $19.06 | 2019 | |
| Zimmer Biomet Holdings, INC. | $17.62 | 2019 | |
| Shire North American Group INC | $16.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.84 | 2019 | |
| Radius Health, INC. | $12.28 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $11.68 | 2019 | |
| Merck Sharp & Dohme LLC | $11.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.